BRCA2 and breast carcinoma: First, 22 women in the TCGA ovarian cancer category had BRCA1 or BRCA2 germline mutations, while another 27 in the control group had BRCA1 or BRCA2 mutations (these were breast cancer patients, included here as controls because they were non-ovarian cancer women patients) [32].